Kezar Life Sciences, INC 8-K filings

Kezar Life Sciences, Inc. has been acquired by Aurinia Pharma U.S., Inc. following the successful completion of a tender offer and subsequent merger.

Kezar Life Sciences announced the termination of a significant lease agreement and the departure of its CEO, CFO, and COO, coinciding with details of its pending acquisition by Aurinia Pharmaceuticals.

Kezar Life Sciences agreed to a tender offer from Aurinia Pharma U.S. at $6.955 per share in cash plus a non‑tradable CVR tied to zetomipzomib, collaboration proceeds and excess net cash, with closing targeted for Q2 2026.

Kezar Life Sciences divests its Sec61-based discovery and development program, including KZR-261, to Enodia Therapeutics for an upfront payment and up to $127 million in milestones plus royalties.

Kezar Life Sciences announced third-quarter 2025 financial results, revealing a significant workforce reduction and a strategic review following an FDA setback for its lead drug candidate, zetomipzomib.

Kezar Life Sciences, Inc. announced a significant restructuring plan on November 6, 2025, reducing its workforce by approximately 70% and anticipating $6.0 million in related costs.

Kezar Life Sciences, Inc. announced the full repayment of $6.3 million and termination of its Loan and Security Agreement with Oxford Finance LLC, utilizing cash on hand.

Kezar Life Sciences announced a regulatory setback for its zetomipzomib program in autoimmune hepatitis, leading the company to explore strategic alternatives and extend its shareholder rights plan.

Kezar Life Sciences announced second quarter 2025 financial results, highlighted by the FDA's removal of a partial clinical hold on its PORTOLA trial for autoimmune hepatitis and plans for a registration-enabling study.

Kezar Life Sciences, Inc. announced the results of its annual stockholders' meeting on June 17, 2025, where stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified KPMG LLP as its independent auditor.

Kezar Life Sciences announced positive topline data from its PORTOLA Phase 2a clinical trial for autoimmune hepatitis (AIH) and reported a cash balance of $114.4 million as of March 31, 2025.

Kezar Life Sciences appoints Pichi Chiang as its new Principal Accounting Officer, effective April 1, 2025, succeeding Marc Belsky in that role.

Kezar Life Sciences reports positive topline results from the PORTOLA Phase 2a trial of zetomipzomib in autoimmune hepatitis (AIH), showing steroid-sparing biochemical remissions and reports year end 2024 financial results.

Kezar Life Sciences presented an update on zetomipzomib's clinical development, including safety data from the PALIZADE Phase 2b trial in lupus nephritis and the design of the PORTOLA trial in autoimmune hepatitis, during a virtual Key Opinion Leader event.

Kezar Life Sciences estimates its cash, cash equivalents, and marketable securities at approximately $132.2 million with 7.3 million shares outstanding as of December 31, 2024.

Kezar Life Sciences has amended its Rights Agreement to clarify the Board of Directors' authority in administering the agreement.

Kezar Life Sciences has regained compliance with Nasdaq listing rules after its stock price closed above $1.00 for ten consecutive business days.

Kezar Life Sciences announced its third quarter 2024 financial results, provided an update on its clinical trials, and reported a strategic shift in focus to its autoimmune hepatitis program.

Kezar Life Sciences has executed a 1-for-10 reverse stock split to meet Nasdaq's minimum bid price requirement, effective October 29, 2024.

Kezar Life Sciences rejects a $1.10 per share acquisition proposal from Concentra Biosciences, adopts a limited duration stockholder rights plan, and provides an update on its clinical trials.

Kezar Life Sciences has received an unsolicited, non-binding proposal from Concentra Biosciences to acquire all outstanding shares for $1.10 per share plus a contingent value right.

Kezar Life Sciences' zetomipzomib IND for lupus nephritis treatment has been placed on clinical hold by the FDA following fatal adverse events in a Phase 2b trial.

Kezar Life Sciences has voluntarily stopped enrolling new patients and dosing current patients in its Phase 2b PALIZADE trial for lupus nephritis due to safety concerns, including four fatal adverse events.

Kezar Life Sciences reported its Q2 2024 financial results, completed enrollment in the PORTOLA trial, revised topline data guidance for PORTOLA to the first half of 2025, and stopped enrollment in the KZR-261 Phase 1 study.

Kezar Life Sciences held its annual meeting, electing two directors, not approving executive compensation, and approving a reverse stock split.

Kezar Life Sciences has been granted an extension to regain compliance with Nasdaq's minimum bid price rule after transferring to the Nasdaq Capital Market.

Kezar Life Sciences announced its first quarter 2024 financial results and provided updates on its ongoing clinical trials for zetomipzomib and KZR-261.

Kezar Life Sciences announced its year-end 2023 financial results and provided updates on its clinical programs, including the PALIZADE and PORTOLA trials for zetomipzomib and the KZR-261 dose escalation study.